ImmunityBio to Distribute ANKTIVA in 33 European Countries After 71% Response Rate
ImmunityBio has partnered with Accord Healthcare to distribute its bladder cancer therapy ANKTIVA across 33 European countries. ANKTIVA achieved a 71% complete response rate in BCG-unresponsive non-muscle invasive bladder cancer and is approved in the U.S., EU, UK and Saudi Arabia while the company advances its IL-15 receptor agonist platform.
1. Partnership Expansion
ImmunityBio has entered a strategic distribution agreement with Accord Healthcare to make its immunotherapy ANKTIVA available to bladder cancer patients in 33 European countries, leveraging Accord’s established network to accelerate market penetration across key EU markets.
2. Clinical Efficacy and Approvals
ANKTIVA demonstrated a 71% complete response rate in BCG-unresponsive non-muscle invasive bladder cancer during clinical studies, and holds regulatory approvals in the U.S., European Union, United Kingdom and Saudi Arabia, positioning it as a best-in-class therapy for high-unmet-need patients.
3. Platform Development
Beyond ANKTIVA, ImmunityBio is advancing its IL-15 receptor agonist platform aimed at enhancing natural killer and T-cell activity, with multiple preclinical and early-stage oncology programs designed to expand its pipeline of next-generation immunotherapies.